Loading stock…

Charles River Laboratories International, Inc. (CRL) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Charles River Laboratories International, Inc.

CRLMarket cap $14BPrice $300.3

Country🇺🇸United States

SectorHealthcare

IndustryLife Sciences

Runs the labs that test new drugs before they ever reach humans, breeding and supplying research animals, running toxicology studies, and supporting nearly every major pharma pipeline. If a drug's in trials, there's a good chance Charles River touched it first.

In Bastion Portfolios?

52W Return+68%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+0%3

Revenue Forecast

Rev CAGR (1y)-3%2

Rev CAGR (3y)+2%2

Rev CAGR (5y)+4%3

Earnings Forecast

EPS Growth Y+1+5699%10

EPS Growth Y+2+12%7

EPS Growth Y+3+11%7

Quality

Margins

EBIT Margin12%5

Net Income Margin-6%1

Free Cash Flow Margin9%6

Debt

Net Debt/EBITDA3.03

Efficiency

ROE-8%1

ROA-3%2

Earnings Stability77

GEAR+VERY WEAK9

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)253

P/E Ratio (Forward 3y)213

P/BV5.03

EV Multiples

EV/EBITDA Fwd173

EV/EBIT Fwd214

Yield

Free Cash Flow Yield2.6%4

Dividend Yieldna–

Momentum

Short term

1 month return+7%10

3 month return+34%10

YTD return+51%9

Mid term

Price vs 52wHigh90%8

1 year return+73%10

Long term

3 year return+55%6

5 year return-27%2

Risk Shield

Price Risk

Beta0.85

Volatility45%4

Free Cash Flow

Free Cash Flow Margin9%6

Free Cash Flow Yield2.6%4

Quality

ROCE8%5

Earnings Stability77

Net Debt/EBITDA3.03

02Growth

Is it actually growing, and how fast?

CRLCharles River Laboratories International

Revenue FY25$4.0B

GROWTH RATING↗

WEAK20 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+0%3

Revenue, next 1Y-3%2

Revenue, next 3Y, CAGR+2%2

Revenue, next 5Y, CAGR+4%3

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+5699%10

EPS growth, FY27E+12%7

EPS growth, FY28E+11%7

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

Revenue held flat over the last 3 years and is set to keep growing around 2%/yr.

WEAKNESSES

Growth is the weak spot here, trailing 80% of companies worldwide.

Revenue held flat over the last 3 years, behind 70% of companies worldwide.3/10

Revenue is set to grow 2%/yr over the next 3 years, behind most of the market.2/10

Over five years revenue is set to grow 4%/yr, behind 70% of companies worldwide.3/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Stalled Business

Growth is a weak point here. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG85 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+7%10

3-month return+34%10

YTD return+51%9

MID & LONG-TERM▾SCORE

% of 52-week high90%8

1-year return+73%10

3-year return+55%6

5-year return-27%2

MOMENTUM ASSESSMENT

STRENGTHS

It's up 73% over the past year, but 10% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+7%), over three months (+34%) and so far this year (+51%).

WATCH

Average long-term results. Multi-year returns are middling (+55% over three years and -27% over five), roughly average for the market.

WEAKNESSES

None flagged.

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case.

04Value

Are you paying a fair price for it?

Stop guessing on Charles River. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

CRLCharles River Laboratories International

Revenue FY25$4.0B

GROWTH RATING↗

WEAK20 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+0%3

Revenue, next 1Y-3%2

Revenue, next 3Y, CAGR+2%2

Revenue, next 5Y, CAGR+4%3

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+5699%10

EPS growth, FY27E+12%7

EPS growth, FY28E+11%7

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

Revenue held flat over the last 3 years and is set to keep growing around 2%/yr.

WEAKNESSES

Growth is the weak spot here, trailing 80% of companies worldwide.

Revenue held flat over the last 3 years, behind 70% of companies worldwide.3/10

Revenue is set to grow 2%/yr over the next 3 years, behind most of the market.2/10

Over five years revenue is set to grow 4%/yr, behind 70% of companies worldwide.3/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Stalled Business

Growth is a weak point here. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG85 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+7%10

3-month return+34%10

YTD return+51%9

MID & LONG-TERM▾SCORE

% of 52-week high90%8

1-year return+73%10

3-year return+55%6

5-year return-27%2

MOMENTUM ASSESSMENT

STRENGTHS

It's up 73% over the past year, but 10% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+7%), over three months (+34%) and so far this year (+51%).

WATCH

Average long-term results. Multi-year returns are middling (+55% over three years and -27% over five), roughly average for the market.

WEAKNESSES

None flagged.

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case.

04Value

Are you paying a fair price for it?

Stop guessing on Charles River. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community